CV Therapeutics^® is a biopharmaceutical company primarily focused on the discovery, development and commercialization of new small molecule drugs for the treatment of cardiovascular diseases. We apply advances in molecular biology and genetics to identify mechanisms of cardiovascular diseases and targets for drug discovery.

	More News
+ CV Therapeutics Reports 2008 First Quarter Financial Results + European Medicines Agency Adopts Positive Opinion for Ranolazine for Treatment of Chronic Angina + CV Therapeutics Announces $185 Million Transaction with TPG-Axon Capital for Half of Royalty for Lexiscan(TM) (regadenoson) Injection

	Learn More
CV Therapeutics is looking for talented professionals to work in a rapidly growing, results-oriented, progressive research and development environment...